and continued supply of OFIRMEV to successfully launch commercial sales or meet anticipated market demand; our ability to comply with the terms of our loan agreement, and draw down additional amounts under our loan agreement; the potential for an event of default under our loan agreement, and the corresponding risk of acceleration of repayment and potential foreclosure on the assets pledged to secure the line of credit; the impact of healthcare reform legislation; our ability to timely complete a required post-marketing efficacy study of OFIRMEV in infants and neonates; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Cadence® and OFIRMEV™ are trademarks of Cadence Pharmaceuticals, Inc.Contact:
William R. LaRue
Nicole FoderaroSVP & Chief Financial Officer
Media & Investor RelationsCadence Pharmaceuticals, Inc.
415-946-1058 – office415-215-5643 – cellCADENCE PHARMACEUTICALS, INC.(a development stage company)CONDENSED STATEMENTS OF OPERATIONS(unaudited)Three Months EndedNine Months EndedSeptember 30,September 30,2010 2009 2010 2009 Operating expenses:Research and development
4,683,908Sales and marketing
4,129,0083,068,63214,857,9584,790,886General and administrative
Page: 1 2 3 4 5 6 Related medicine technology :1
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule2
. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update3
. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 20084
. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline5
. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update6
. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever7
. Cadence Pharmaceuticals to Webcast October 7th Analyst Day8
. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 20099
. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 200910
. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months11
. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals